RXi Pharmaceuticals is a clinical-stage company developing therapeutics based on its self-delivering RNAi (sd-rxRNA®) platform and Samcyprone™, a topical immunomodulator. Co.'s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone™, for the treatment of warts. Co.'s development programs also include cell-based cancer immunotherapy. Co.'s RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its topical immunotherapy agent, Samcyprone™, treats diseases by inducing, enhancing or suppressing an immune response in the skin. We show 4 historical shares outstanding datapoints in our RXII shares outstanding history coverage, used to compute RXII market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RXII market cap history over the course of time is important for investors
interested in comparing RXII's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RXII versus a peer is one thing; comparing
RXII market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RXII can fluctuate over the course of history.
With this page we aim to empower investors researching RXII by allowing them to research the RXII market cap history. |
Free RXII Email Alerts:
Video: The Importance of Market Cap
